Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab maintenance with or without erlotinib after first-line chemotherapy in advanced non-small cell lung cancer
2006-006624-19Phase 3Completed
- Sponsor
- Genentech
- Start
- Feb 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Bevacizumab + erlotinib with Bevacizumab + placebo (2 arms). Primary endpoint: Post-chemotherapy progression-free survival. Started Feb 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-006624-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006624-19.